Fresenius Medical Care Analyst Ratings
Fresenius Medical Care Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/11/2023 | 39.53% | Truist Securities | $28 → $24 | Maintains | Hold |
| 07/13/2023 | 62.79% | Truist Securities | $26 → $28 | Maintains | Hold |
| 05/10/2023 | 51.16% | Truist Securities | $24 → $26 | Maintains | Hold |
| 04/13/2023 | 39.53% | Truist Securities | $22 → $24 | Maintains | Hold |
| 02/23/2023 | 27.91% | Truist Securities | $17 → $22 | Maintains | Hold |
| 06/22/2022 | 56.98% | Truist Securities | $34 → $27 | Maintains | Hold |
| 11/23/2021 | — | HSBC | Initiates Coverage On | → Hold | |
| 11/17/2021 | 103.49% | RBC Capital | $42 → $35 | Maintains | Sector Perform |
| 11/11/2021 | — | Jefferies | Upgrades | Underperform → Hold | |
| 05/21/2020 | 179.07% | SunTrust Robinson Humphrey | $46 → $48 | Maintains | Buy |
| 05/11/2020 | 167.44% | SunTrust Robinson Humphrey | $42 → $46 | Maintains | Buy |
| 04/13/2020 | 144.19% | SunTrust Robinson Humphrey | $46 → $42 | Maintains | Buy |
| 02/21/2020 | 167.44% | CFRA | $38 → $46 | Upgrades | Hold → Buy |
| 01/21/2020 | — | Jefferies | Upgrades | Hold → Buy | |
| 10/23/2019 | — | Redburn Partners | Downgrades | Buy → Neutral | |
| 08/01/2019 | — | BTIG | Downgrades | Buy → Neutral | |
| 06/20/2019 | — | Barclays | Upgrades | Equal-Weight → Overweight | |
| 10/26/2018 | — | UBS | Upgrades | Neutral → Buy | |
| 10/18/2018 | — | DZ Bank | Downgrades | Buy → Hold |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 2023 年 11 月 10 日 | 39.53% | 信實證券 | 28 美元 → 24 美元 | 維護 | 保持 |
| 07/13/2023 | 62.79% | 信實證券 | 26 美元 → 28 美元 | 維護 | 保持 |
| 05/10/2023 | 51.16% | 信實證券 | 24 美元 → 26 美元 | 維護 | 保持 |
| 04/13/2023 | 39.53% | 信實證券 | 22 美元 → 24 美元 | 維護 | 保持 |
| 02/23/2023 | 27.91% | 信實證券 | 17 美元 → 22 美元 | 維護 | 保持 |
| 06/22/2022 | 56.98% | 信實證券 | 34 美元 → 27 美元 | 維護 | 保持 |
| 11/23/2021 | — | 匯豐銀行 | 啓動覆蓋範圍開啓 | → 按住 | |
| 11/17/2021 | 103.49% | 加拿大皇家銀行資本 | 42 美元 → 35 美元 | 維護 | 行業表現 |
| 11/11/2021 | — | 傑富瑞 | 升級 | 表現不佳 → 持有 | |
| 05/21/2020 | 179.07% | SunTrust 羅賓遜·漢弗萊 | 46 美元 → 48 美元 | 維護 | 購買 |
| 05/11/2020 | 167.44% | SunTrust 羅賓遜·漢弗萊 | 42 美元 → 46 美元 | 維護 | 購買 |
| 2020 年 4 月 13 日 | 144.19% | SunTrust 羅賓遜·漢弗萊 | 46 美元 → 42 美元 | 維護 | 購買 |
| 02/21/2020 | 167.44% | CFRA | 38 美元 → 46 美元 | 升級 | 持有 → 買入 |
| 2020 年 1 月 21 日 | — | 傑富瑞 | 升級 | 持有 → 買入 | |
| 2019 年 10 月 23 日 | — | Redburn 合作伙伴 | 降級 | 買入 → 中性 | |
| 08/01/2019 | — | BTIG | 降級 | 買入 → 中性 | |
| 06/20/2019 | — | 巴克萊 | 升級 | 重量相等 → 超重 | |
| 2018 年 10 月 26 日 | — | 瑞銀（UBS） | 升級 | 中性 → 買入 | |
| 10/18/2018 | — | DZ 銀行 | 降級 | 買入 → 持有 |
What is the target price for Fresenius Medical Care (FMS)?
費森尤斯醫療（FMS）的目標價格是多少？
The latest price target for Fresenius Medical Care (NYSE: FMS) was reported by Truist Securities on October 11, 2023. The analyst firm set a price target for $24.00 expecting FMS to rise to within 12 months (a possible 39.53% upside). 5 analyst firms have reported ratings in the last year.
Truist Securities於2023年10月11日公佈了費森尤斯醫療（紐約證券交易所代碼：FMS）的最新目標股價。該分析公司將目標股價定爲24.00美元，預計FMS將在12個月內上漲至39.53％（可能上漲39.53％）。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for Fresenius Medical Care (FMS)?
費森尤斯醫療（FMS）的最新分析師評級是多少？
The latest analyst rating for Fresenius Medical Care (NYSE: FMS) was provided by Truist Securities, and Fresenius Medical Care maintained their hold rating.
費森尤斯醫療（紐約證券交易所代碼：FMS）的最新分析師評級由Truist Securities提供，費森尤斯醫療維持其持倉評級。
When is the next analyst rating going to be posted or updated for Fresenius Medical Care (FMS)?
費森尤斯醫療（FMS）的下一份分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fresenius Medical Care, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fresenius Medical Care was filed on October 11, 2023 so you should expect the next rating to be made available sometime around October 11, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與費森尤斯醫療的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。費森尤斯醫療的最新評級是在2023年10月11日提交的，因此你應該預計下一個評級將在2024年10月11日左右公佈。
Is the Analyst Rating Fresenius Medical Care (FMS) correct?
分析師對費森尤斯醫療（FMS）的評級是否正確？
While ratings are subjective and will change, the latest Fresenius Medical Care (FMS) rating was a maintained with a price target of $28.00 to $24.00. The current price Fresenius Medical Care (FMS) is trading at is $17.20, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但費森尤斯醫療（FMS）的最新評級保持不變，目標價爲28.00美元至24.00美元。費森尤斯醫療（FMS）目前的交易價格爲17.20美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。